1. Research
  2. Growth Control and Cancer Metastasis
  3. Growth Control and Cancer Metastasis publications

Growth Control and Cancer Metastasis publications

The RNA binding protein CPEB2 regulates hormone sensing in mammary gland development and luminal breast cancer
Pascual R, Martín J, Salvador F, Reina O, Chanes V, Millanes-Romero A, Suñer C, Fernández-Miranda G, Bartomeu A, Huang YS, Gomis RR and Méndez R.
Sci Adv, 6 (20), eaax3868 (2020)
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer
Hermanova I, Zúñiga-García P, Caro-Maldonado A, Fernandez-Ruiz S, Salvador F, Martín-Martín N, Zabala-Letona A, Nuñez-Olle M, Torrano V, Camacho L, Lizcano JM, Talamillo A, Carreira S, Gurel B, Cortazar AR, Guiu M, López JI, Martinez-Romero A, Astobiza I, Valcarcel-Jimenez L, Lorente M, Arruabarrena-Aristorena A, Velasco G, Gomez-Muñoz A, Suárez-Cabrera C, Lodewijk I, Flores JM, Sutherland JD, Barrio R, de Bono JS, Paramio JM, Trka J, Graupera M, Gomis RR and Carracedo A.
J Exp Med, 217 (6), (2020)
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
Brasó-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Llombart-Cussac A, Bermejo B, Oliveira M, Morales S, Martínez N, Vidal M, Adamo B, Martínez O, Pernas S, López R, Muñoz M, Chic N, Galván P, Garau I, Manso L, Alarcón J, Martínez E, Gregorio S, Gomis RR, Villagrasa P, Cortés J, Ciruelos E and Prat A.
Nat Commun, 11 (1), 385 (2020)
Survival skills ensure that cancer spreads
Gomis RR.
Nature, 573 (7774), 353-354 (2019)
From latency to overt bone metastasis in breast cancer: potential for treatment and prevention
Salvador F, Llorente A and Gomis RR.
J Pathol, 249 (1), 6-18 (2019)
Correction: The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21
Soria-Valles C, Gutiérrez-Fernández A, Guiu M, Mari B, Fueyo A, Gomis RR and López-Otín C.
Oncogene (2019)
Regulation of death receptor signaling by the autophagy protein TP53INP2
Ivanova S, Polajnar M, Narbona-Perez AJ, Hernandez-Alvarez MI, Frager P, Slobodnyuk K, Plana N, Nebreda AR, Palacin M, Gomis RR, Behrends C and Zorzano A.
Embo J, 38 (10), (2019)
Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer
Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA and Gomis RR.
Nat Cell Biol, 20 (8), 990 (2018)
Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer
Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M and Prat A.
Cancer Treat Rev, 67 63-70 (2018)
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D, Bowman A, Liversedge V, De Boer RH, Passos-Coelho JL, O'Reilly S, Bertelli G, Joffe J, Brown JE, Wilson C, Tercero JC, Jean-Mairet J, Gomis R and Cameron D.
J Bone Oncol, 13 123-135 (2018)

* shared senior authorship